Patients with active MS had lower CD4+ counts (0.602 ± 0.074 × 109/L) whereas MS patients with no previous therapy had CD4+ counts (1.065 ± 0.154 × 109/L) similar to HD (0.990 ± 0.088 × 109/L). This evidence concerns the gene CD4 and myeloid sarcoma.